Verisante Technology Inc (VRS.H)

[fireslayer96]

MELA VS VRSEF HEATING UP!

Mela Sciences Inc. Risking default?

It's probably true that a company would be hard-pressed to do worse than Mela Sciences Inc. (MELA) has managed recently, but it doesn't automatically follow that conditions will get any better for them. In fact, MELA looks to be on the brink of being de-listed from NASDAQ Exchange. Additionally, the company has a brand new hard loan to pay off at the premium interest rate of 10%. So although I am bullish on the prospects for the general idea of a company stepping forward and dominating the early skin cancer detection market, MELA is not where my bullish sentiments lie.

Opportunity for Verisante Technology Inc.

With that very bearish intro in hand, I turn my attentions to Verisante Technology Inc. (VRSEF). This company has just begun sales of its flagship product, The Verisante Aura. This device detects all forms of skin cancers, including pre-cancers, within an impressive two seconds. And the technology is fully able to be expanded into the detection of other internal cancers, such as lung, colon and cervical cancers. Another device in the pipeline is a lower cost skin and oral cancer detection system which is expected to be available with a beta unit before the end of the 2013.

MELA and VRSEF expected to begin major promotions

On January 3 of this year MELA announced that they hired Rpr Marketing Communications to provide a full range of marketing communications based services, including consumer and media relations, corp comm, professional meeting strategy implementation and special initiative management. This Manhattan based agency promotes its company as having extensive experience within the aesthetic medicine, personal maintenance and general skincare industries. Six weeks into the marketing agreement, MELA shareholders and financial analysts have yet to see a widespread promotional blitz.

Within the past two weeks VRSEF announced two Investor Relations firms will take over the promotional components for the company, namely Hazam Thindal Capital Corporation based on the west coast of North America and Crescendo Communications based in New York City. This dual pronged IR approach looks to provide a promotional double-whammy that very well could take the medical technology market by media storm.

The FDA Rules

To say that MELA had some issues with the FDA is like saying that Tiger Woods can play a decent golf game. Well, that doesn't even make sense or equate. But you know what I mean! MELA tried to get the device approved by the FDA between June 2009 and November 2011. It was only after the filing of a citizen's petition with the agency that the FDA decided to approve the MelaFind device, and even this celebratory approval was contentious. Nearly half of the panel voted against approving the MelaFind device or abstained from voting, putting a sour taste on the approval stamp.

VRSEF is expected to receive feedback from the FDA very soon. This feedback should include details to whether the device can be fast-tracked based on clinical data received to this point, or whether a series of US based trials at large skin care centers will be necessary before the PMA application is submitted.

Market Capitalization nearly the same

The market capitalization's of MELA ($47m) and VRSEF ($38m) are nearing each other. 2013 looks to provide a very clear indication on the future of the early skin cancer detection market.

http://finance.yahoo.com/echarts?s=VRS.V#symbol=vrs.v;range=6m;compare=mela;indicator=volume;charttype